EGFR and breast carcinoma: Similar to other cell lines, metformin also induces AMPK activation, reduced the phosphorylation of epidermal growth factor receptor (EGFR), mitogen activated protein kinases (MAPKs) and Src and lowered the levels of cyclins D1 and E in breast cancer cells (362).